$0.32 dividends are now a reality for Bio-Techne Corp (NASDAQ:TECH) shareholders. Here’s why.

February 14, 2018 - By Winifred Garcia

 $0.32 dividends are now a reality for Bio Techne Corp (NASDAQ:TECH) shareholders. Here's why.
Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.23, from 1.44 in 2017Q2. It turned negative, as 16 investors sold Bio-Techne Corporation shares while 86 reduced holdings. 36 funds opened positions while 87 raised stakes. 35.91 million shares or 2.04% less from 36.66 million shares in 2017Q2 were reported.
Glenmede Na owns 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 2,515 shares. Sentinel Asset Mngmt Inc has invested 0.34% in Bio-Techne Corporation (NASDAQ:TECH). Confluence Investment Mngmt Lc accumulated 31,148 shares. Jackson Square Prtn Lc owns 861,616 shares. Advisory Services Limited Liability Corp owns 73 shares. Gotham Asset Lc reported 0.05% in Bio-Techne Corporation (NASDAQ:TECH). Blackrock stated it has 3.58M shares or 0.02% of all its holdings. Veritable L P stated it has 4,715 shares. Mackenzie Corporation holds 570,301 shares or 0.37% of its portfolio. 2,827 are held by Leucadia Natl Corp. Stephens Mgmt Gru Lc holds 0.29% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH) for 102,550 shares. Louisiana State Employees Retirement Sys holds 10,000 shares. United Kingdom-based Mondrian Invest Ltd has invested 0.12% in Bio-Techne Corporation (NASDAQ:TECH). Baystate Wealth Mgmt Lc has invested 0% in Bio-Techne Corporation (NASDAQ:TECH). Nuveen Asset Ltd Liability Com invested in 0% or 1,983 shares.

Since September 6, 2017, it had 0 insider buys, and 3 selling transactions for $153,199 activity. 100 shares were sold by LUCAS ROGER C, worth $12,094 on Friday, September 8.

Bio-Techne Corp (NASDAQ:TECH) is expected to pay $0.32 on Mar 2, 2018. The indicated annual dividend is $1.28. Shareholders owning the stock before Feb 15, 2018 will be eligible to receive the payout. Based on Bio-Techne Corp’s current price of $137.00, the dividend is 0.23 %. This dividend’s record date is Feb 16, 2018 and the announcement date is Feb 6, 2018. The stock increased 1.15% or $1.56 during the last trading session, reaching $137. About 233,878 shares traded or 36.01% up from the average. Bio-Techne Corporation (NASDAQ:TECH) has risen 6.75% since February 14, 2017 and is uptrending. It has underperformed by 9.95% the S&P500.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.13 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 45.05 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 9 analysts covering BIO-TECHNE Corp (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. BIO-TECHNE Corp has $160.0 highest and $93 lowest target. $134.14’s average target is -2.09% below currents $137 stock price. BIO-TECHNE Corp had 22 analyst reports since August 18, 2015 according to SRatingsIntel. Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) on Monday, October 23 with “Buy” rating. Janney Capital downgraded the stock to “Neutral” rating in Monday, March 27 report. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Hold” rating by Wells Fargo on Thursday, July 13. The firm has “Buy” rating by Janney Capital given on Tuesday, May 3. The firm earned “Buy” rating on Tuesday, February 6 by Robert W. Baird. The rating was initiated by Citigroup on Thursday, February 9 with “Buy”. The firm has “Hold” rating given on Tuesday, September 22 by Zacks. The company was maintained on Wednesday, August 9 by Deutsche Bank. As per Wednesday, February 7, the company rating was maintained by Craig Hallum. As per Thursday, October 29, the company rating was downgraded by Stephens.

More important recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Seekingalpha.com which released: “Bio-Techne Acquires Trevigen In All Cash Deal” on September 07, 2017, also Seekingalpha.com published article titled: “Bio-Techne (TECH) Q4 2017 Results – Earnings Call Transcript”, Seekingalpha.com published: “Bio-Techne (TECH) Q1 2018 Results – Earnings Call Transcript” on October 31, 2017. More interesting news about Bio-Techne Corporation (NASDAQ:TECH) was released by: Nasdaq.com and their article: “Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 09, 2017” with publication date: November 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.